Daniel Jones, M.D., Ph.D.

SARS-CoV-2 genomics, immune and host genomic predictors of COVID-19 disease severity and defining critical genomic features in the progression and therapy resistance of lymphoid and myeloid leukemia. Projects include novel design of NGS virus and host immune assays, bioinformatics strategies to characterize uncommon sequence variants in cancer associated genes and TP53 and PALB2 structure function models.